Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Core Insights - Lyell Immunopharma, Inc. is advancing a pipeline of next-generation CAR T-cell therapies for cancer patients, with new clinical data for LYL314 to be presented at the ICML 2025 [1][2] - LYL314 is a dual-targeting CD19/CD20 CAR T-cell product candidate specifically for aggressive large B-cell lymphoma, having received FDA designations for advanced therapy and fast track [2] Company Overview - Lyell is a clinical-stage company focused on CAR T-cell therapies for hematologic malignancies and solid tumors, employing technologies to enhance CAR T-cell durability and efficacy in challenging tumor environments [3] Presentation Details - The presentation on LYL314 will occur on June 18, 2025, at 5:40 pm CEST, featuring Dr. Akil Merchant from Cedars-Sinai Medical Center [5]